|
| |
XOMAXOMA is a leading biopharmaceutical company in the field of therapeutic antibody discovery and development. We have a royalty interest in one approved therapeutic antibody, RAPTIVA® (efalizumab), which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. We also have royalty interests in additional therapeutic antibody product candidates being developed by others as a result of licensing our technologies. XOMA’s pipeline includes both proprietary products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. XOMA has contributed key innovations to the field of therapeutic antibodies. Today we possess an exceptionally broad technology platform for the discovery, optimization and manufacture of therapeutic antibodies as well as a fully integrated product development infrastructure for antibodies and other biologics.
| Contact Details: |
| 2910 Seventh Street |
| Berkeley |
| CA |
| 94710 |
| United States of America |
| Tel: | 510 204-7200 |
| Fax: | 510 644 2011 |
| Email: | InvestorRelations@xoma.com |
| WWW: | www.xoma.com/
|
|
Loading...
|
Recent Publications by XOMA: |  |
Development of XPA067.06, a potent high affinity human anti-gastrin monoclonal antibody.
The peptide hormone gastrin is a key factor in regulation of gastric acid... | 5th August, 2008
| Preclinical Research & Development, XOMA (US) LLC, 2910 Seventh Street,
| Biochem Pharmacol. 2008 Aug 1;76(3):340-52. Epub 2008 May 24.
DOI Direct Link |
Activation of human NK cells by the bacterial pathogen-associated molecular pattern muramyl dipeptide.
Muramyl dipeptide (MDP) is a bacterial pathogen associated molecular... | 11th June, 2008
| Xoma Ireland Limited, Dublin, Ireland.
| J Immunol. 2008 Mar 15;180(6):4082-9.
|
Physiology and clinical pathology of laboratory new zealand white rabbits housed individually and in groups.
Rabbits used in the production of antibodies can be housed individually or... | 7th May, 2008
| Bayer HealthCare, Pharmaceuticals,
| J Am Assoc Lab Anim Sci. 2008 Mar;47(2):35-8.
|
Recent advances in immunoinformatics: application of in silico tools to drug development.
Immunoinformatics is an emerging specialization of bioinformatics that... | 15th April, 2008
| Research Informatics, Preclinical Research and Development, XOMA (US) LLC,
| Curr Opin Drug Discov Devel. 2008 Mar;11(2):233-41.
|
Rational design and optimization of fed-batch and continuous fermentations.
This chapter provides rational approaches to design and optimize fed-batch... | 20th December, 2007
| Xoma Ltd., Berkey, CA.,USA.
| Methods Mol Biol. 2007;389:43-64.
|
→View more XOMA research publications. |
Press Releases on XOMA:
|
 |
| ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours |
16th November, 2009 |
|
LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase I
|
| VIVUS Announces Promotion of Peter Tam to President |
3rd November, 2009 |
VIVUS, Inc. |
MOUNTAIN VIEW, Calif., Nov. 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced the promotion of Peter Tam to president of VIVUS. In this position, Mr. Tam will lead and have
|
| Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009 |
27th October, 2009 |
Cephalon, Inc. |
FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2009 net sales of $535.2 million, a 9 percent increase compared to net sales of $489.7
|
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications |
26th October, 2009 |
Reportlinker |
NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional
|
BioNews Results for XOMA:  | |
| XOMA 052 Selected as a Top Ten Project to Watch |
XOMA: Nov 15 2009 7:36AM Matching: xoma
|
| XOMA Announces Presentation at Lazard Healthcare Conference on November 18 |
Pharma Live: Nov 13 2009 7:06AM Matching: xoma
|
| Financial & Company Analysis on MMM, BEAV, ACAS, XOMA, CEDC and A... |
Zibb: Nov 13 2009 12:59PM Matching: xoma
|
| Financial & Company Analysis on MMM, BEAV, ACAS, XOMA, CEDC and ARCC From TheFortuneFinancial.com |
NewsBlaze: Nov 13 2009 11:45AM Matching: xoma
|
| Financial & Company Analysis on MMM, BEAV, ACAS, XOMA, CEDC and ARCC From TheFortuneFinancial.com |
Marketwire via Yahoo!: Nov 13 2009 11:57AM Matching: xoma
|
| Promote your company here: BioNewsCast - Press Release Distribution | →View more XOMA news. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 25 individuals from XOMA using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 689 times since April 2007, the link to the organisation's website has been followed 108 times Recent Search Terms used to find this page: Xoma Ltd and European patent | Xoma Ltd and European patent | Cephalon Inc. xoma | xoma ireland limited | Affitech xoma | quote xoma april 2007 | NASDAQ XOMA seeking alpha | steve engle xoma | STEVE ENGLE XOMA JUNE 2009 | xoma | . Search for more companies in Berkeley Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for XOMA |
